TY - JOUR
T1 - Triglyceride-mediated pathways and coronary disease
T2 - Collaborative analysis of 101 studies
AU - Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration
AU - Sarwar, Nadeem
AU - Sandhu, Manjinder S.
AU - Ricketts, Sally L.
AU - Butterworth, Adam S.
AU - Di Angelantonio, Emanuele
AU - Matthijs Boekholdt, S.
AU - Ouwehand, Willem
AU - Watkins, Hugh
AU - Samani, Nilesh J.
AU - Saleheen, Danish
AU - Lawlor, Debbie
AU - Reilly, Muredach P.
AU - Hingorani, Aroon D.
AU - Talmud, Philippa J.
AU - Danesh, John
AU - Braund, P. S.
AU - Hall, A. S.
AU - Thompson, J.
AU - Marz, W.
AU - Trip, M.
AU - Lawlor, D. A.
AU - Sivapalaratnam, S.
AU - Soranzo, N.
AU - Arsenault, B. J.
AU - Boekholdt, S. M.
AU - Khaw, K. T.
AU - Wareham, N. J.
AU - Grallert, H.
AU - Illig, T.
AU - Humphries, S. E.
AU - Rader, D. J.
AU - Clarke, R.
AU - Hamsten, A.
AU - Hopewell, J. C.
AU - Frossard, P.
AU - Deloukas, P.
AU - Ye, S.
AU - Simpson, I. A.
AU - Onat, A.
AU - Komurcu-Bayrak, E.
AU - Martinelli, N.
AU - Olivieri, O.
AU - Girelli, D.
AU - Kivimaki, M.
AU - Kumari, M.
AU - Aouizerat, B. E.
AU - Baum, L.
AU - Campos, H.
AU - Chaaba, R.
AU - Feskens, E. J.M.
N1 - Funding Information:
John Danesh reports receiving research grants from the British Heart Foundation; BUPA Foundation; Denka; diaDexus; European Union; Evelyn Trust; Fogarty International Centre; GlaxoSmithKline; Medical Research Council; Merck; National Heart, Lung, and Blood Institute; National Institute of Neurological Disorders and Stroke; Novartis; Pfizer; Roche; the Wellcome Trust; and UK Biobank. He has served on advisory boards for Merck and Novartis, for which he has received compensation. Aroon D Hingorani reports acting as a consultant for GlaxoSmithKline and as a scientific adviser to London Genetics, and has received honoraria for speaking at educational meetings related to cardiovascular risk. Danish Saleheen reports receiving grants from the Wellcome Trust. Hugh Watkins reports receiving grants from the British Heart Foundation. Philippa J Talmud reports receiving grants from the British Heart Foundation. Adam S Butterworth, Debbie Lawlor, Emanuele Di Angelantonio, Muredach P Reilly, Manjinder S Sandhu, Nadeem Sarwar, Nilesh J Samani, Sally L Ricketts, S Matthijs Boekholdt, and Willem Ouwehand declare that they have no conflicts of interest.
Funding Information:
The coordinating centre was supported by the British Heart Foundation, the UK Medical Research Council, and Novartis. A variety of sources have supported investigators, recruitment, follow-up, and laboratory measurements in the studies contributing to this report. Investigators of several of these studies have contributed to a list naming some of these funding sources, which can be found at http://www.phpc.cam.ac.uk/ceu/ . S Shah assisted with provision of tabular data.
Publisher Copyright:
© 2010, The Lancet. All rights reserved.
PY - 2010
Y1 - 2010
N2 - Summary Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality. Methods We assessed the –1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent diff erences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2・79 million person-years at risk). We analysed –1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy. Findings The minor allele frequency of –1131T>C was 8% (95% CI 7–9). –1131T>C was not signifi cantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean diff erence per C allele 3・5% [95% CI 2・6–4・6]; 0・053 mmol/L [0・039–0・068]), lower apolipoprotein AI (1・3% [0・3–2・3]; 0・023 g/L [0・005–0・041]), and higher apolipoprotein B (3・2% [1・3–5・1]; 0・027 g/L [0・011–0・043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16・0% (95% CI 12・9–18・7), or 0・25 mmol/L (0・20–0・29), higher (p=4・4×10–2⁴). The odds ratio for coronary heart disease was 1・18 (95% CI 1・11–1・26; p=2・6×10–⁷) per C allele, which was concordant with the hazard ratio of 1・10 (95% CI 1・08–1・12) per 16% higher triglyceride concentration recorded in prospective studies. –1131T>C was signifi cantly associated with higher VLDL particle concentration (mean diff erence per C allele 12・2 nmol/L [95% CI 7・7–16・7]; p=9・3×10–⁸) and smaller HDL particle size (0・14 nm [0・08–0・20]; p=7・0×10–⁵), factors that could mediate the eff ects of triglyceride. Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease. Funding British Heart Foundation, UK Medical Research Council, Novartis.
AB - Summary Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality. Methods We assessed the –1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20 842 patients with coronary heart disease, 35 206 controls) with that recorded for equivalent diff erences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12 785 incident cases of coronary heart disease during 2・79 million person-years at risk). We analysed –1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy. Findings The minor allele frequency of –1131T>C was 8% (95% CI 7–9). –1131T>C was not signifi cantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean diff erence per C allele 3・5% [95% CI 2・6–4・6]; 0・053 mmol/L [0・039–0・068]), lower apolipoprotein AI (1・3% [0・3–2・3]; 0・023 g/L [0・005–0・041]), and higher apolipoprotein B (3・2% [1・3–5・1]; 0・027 g/L [0・011–0・043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16・0% (95% CI 12・9–18・7), or 0・25 mmol/L (0・20–0・29), higher (p=4・4×10–2⁴). The odds ratio for coronary heart disease was 1・18 (95% CI 1・11–1・26; p=2・6×10–⁷) per C allele, which was concordant with the hazard ratio of 1・10 (95% CI 1・08–1・12) per 16% higher triglyceride concentration recorded in prospective studies. –1131T>C was signifi cantly associated with higher VLDL particle concentration (mean diff erence per C allele 12・2 nmol/L [95% CI 7・7–16・7]; p=9・3×10–⁸) and smaller HDL particle size (0・14 nm [0・08–0・20]; p=7・0×10–⁵), factors that could mediate the eff ects of triglyceride. Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease. Funding British Heart Foundation, UK Medical Research Council, Novartis.
UR - http://www.scopus.com/inward/record.url?scp=77951875017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951875017&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(10)60545-4
DO - 10.1016/S0140-6736(10)60545-4
M3 - Article
C2 - 20452521
AN - SCOPUS:77951875017
SN - 0140-6736
VL - 375
SP - 1634
EP - 1639
JO - The Lancet
JF - The Lancet
IS - 9726
ER -